GMED, US3795772082

Globus Medical stock faces a new Hold view at USD 73.90

Published on 10/08/2026 at 01:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Globus Medical stock posted USD 789.61 million in Q2 revenue on August 6, while adjusted EPS beat consensus by USD 0.24. Shares were last at USD 73.75 on October 7.

GMED, US3795772082, Illustration mit AI erstellt.

Globus Medical stock (ISIN US3795772082) was last at USD 73.75 on the NYSE on October 7, 2026 at 4:00 p.m. ET, down 3.51 percent from the prior close. A new research view places the debate around valuation rather than a fresh operating result.

Hold view sets USD 73.90 target

MCH Advisory published a Hold rating on October 6, 2026, with a 12-month probability-weighted target of USD 73.90. The target lies 0.2 percent above the October 7 price, leaving the research view close to the market level.

The same analysis lists a triangulated fair value of USD 77.79 and says the valuation case depends heavily on the earnings multiple. Its street target is USD 101 based on 15 analysts, which is 36.9 percent above the October 7 price.

Q2 revenue reached USD 789.61 million

MarketBeat reports that Globus Medical posted second-quarter 2026 results on August 6, 2026, with revenue of USD 789.61 million, up 5.9 percent year over year. The figure exceeded the USD 782.88 million consensus estimate by USD 6.73 million.

GAAP EPS was USD 1.34 against a USD 1.10 consensus estimate, a beat of USD 0.24. The company also set fiscal 2026 EPS guidance at USD 4.950-5.050, compared with consensus EPS of USD 4.740, according to MarketBeat.

Stock remains below its yearly high

The October 7 trading range was USD 73.26 to USD 76.66, with volume of 2,473,717 shares. The 52-week range extends from USD 56.50 to USD 101.40, placing the last price 27.3 percent below the yearly high.

Yahoo Finance identifies Globus Medical as a medical devices company listed on the NYSE and shows a market capitalization of USD 10.262 billion on its October 6 quote page. The company develops musculoskeletal products and enabling technologies for spine, orthopedic trauma, joint reconstruction and related procedures.

GMED stock was last at USD 73.75

Globus Medical stock was last at USD 73.75 on the NYSE on October 7, 2026 at 4:00 p.m. ET. The current valuation discussion combines a USD 73.90 research target with second-quarter revenue growth of 5.9 percent and a USD 1.34 GAAP EPS result.